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Cardiovascular homeostasis is maintained in part
by the rapid desensitization of activated heptahelical
receptors that have been phosphorylated by
G protein-coupled receptor kinase 2 (GRK2). How-
ever, during chronic heart failure GRK2 is upregu-
lated and believed to contribute to disease pro-
gression. We have determined crystallographic
structures of GRK2 bound to an RNA aptamer that
potently and selectively inhibits kinase activity. Key
to the mechanism of inhibition is the positioning of
an adenine nucleotide into the ATP-binding pocket
and interactions with the basic aF-aG loop region
of the GRK2 kinase domain. Constraints imposed
on the RNA by the terminal stem of the aptamer
also play a role. These results highlight how a high-
affinity aptamer can be used to selectively trap
a novel conformational state of a protein kinase.
INTRODUCTION
In all eukaryotic cells, the activation of G protein-coupled recep-
tors (GPCRs) leads to profound physiological change, and the
rapid desensitization of these receptors is crucial for an appro-
priate temporal response. One key desensitization mechanism
is initiated by a family of GPCR kinases (GRKs) that phosphory-
lates serine and threonine residues in the intracellular loops and
C-terminal tails of activated GPCRs (Gurevich et al., 2012).
Receptor phosphorylation recruits arrestin, which decreases
heterotrimeric G protein coupling, promotes receptor endocy-
tosis, and initiates new signaling cascades (DeWire et al., 2007).
Although GRKs are critical for the desensitization of GPCRs,
there are pathologies in which GRK activity is maladaptive
(Me´taye´ et al., 2005). One well-studied example is that of
GRK2 in the cardiovasculature (Dorn, 2009). In the normal heart,
activation of myocyte b-adrenergic receptors (b-ARs) by norepi-
nephrine strengthens and increases the rate of contractions.
GRK2 regulates signaling through cardiac b-ARs (Koch et al.,
1995; Kong et al., 1994; Pippig et al., 1993) and other cardiac1300 Structure 20, 1300–1309, August 8, 2012 ª2012 Elsevier Ltd Alreceptors such as the angiotensin and a1-adrenergic receptors
(Cohn et al., 2008; Oppermann et al., 1996), in addition to
regulating catecholamine release in adrenal chromaffin cells
(Lymperopoulos et al., 2008). During the early stages of con-
gestive heart failure, adenylyl cyclase uncouples from b2ARs,
an event that coincides with increased activity and expression
of GRK2. The importance of GRK2 in this process is underscored
by the fact that cardiac-restricted expression of a GRK2 inhibitor
in a mouse model of cardiomyopathy reduces heart failure in
these animals (Rockman et al., 1998).
Therapeutic targeting of GRK2 is complicated by the fact
that it is closely related to six other vertebrate GRKs that
belong to the protein kinase A, G, and C (AGC kinase) family.
Moreover, its catalytic mechanism and active site pocket are
highly conserved among over 500 protein kinases (Johnson,
2009; Manning et al., 2002). Nevertheless, two compounds
from a series of molecules developed by Takeda Pharmaceuti-
cals Company Ltd. exhibited high potency and selectivity toward
GRK2 (Ikeda et al., 2007) by binding to the active site of GRK2
(Thal et al., 2011) in a manner similar to that of the less selective
inhibitor balanol (Tesmer et al., 2010). Surprisingly, their selec-
tivity seemed to be dictated more by the overall shape of the
GRK2 active site than by their interaction with residues that are
unique to each GRK subfamily (Thal et al., 2011).
A high-affinity RNA aptamer that selectively inhibits GRK2
(C13) was recently reported (Mayer et al., 2008). Aptamers
have also been developed for other kinases such as protein
kinase C (Conrad et al., 1994) and mitogen-activated protein
kinase (Seiwert et al., 2000), but the molecular mechanism of
their inhibition is not known. Although RNA aptamers can serve
as therapeutic agents in themselves (Bonetta, 2009), they can
also be useful in identifying small molecule mimetics that dis-
place them from their targets (Hafner et al., 2006; Mayer et al.,
2009). The C13 aptamer contains 20 nucleotides of selected
sequence anchored by a conserved terminal stem region (Mayer
et al., 2008). C13 binds GRK2 with high nanomolar affinity in
a filter-retention assay andwith high selectivity over other protein
kinases, including a 20-fold higher IC50 against closely related
GRK5 (Mayer et al., 2008), which has 45% sequence identity
with GRK2 in the kinase domain. Herein, we use structural and
functional studies to show that C13 stabilizes a unique inactive
conformation of GRK2 through multiple interactions, both withinl rights reserved
Table 1. Sequence, GRK2 Binding, and Inhibition Properties of C13 Variants
Variant
RNA Sequencea
35 40 45 50 55 60 65 70 74 Kd (nM) Activity IC50 (nM)
b Binding IC50 (nM)
c
C13.40 GGGUAGCACAGACCAUACGGGAGAGAAACUUGUGCAACCC 1.3 ± 0.1
C13.29 GGGCAGACCAUACGGGAGAGAAACUUGCC 0.91 ± 0.07
C13.28 GGCAGACCAUACGGGAGAGAAACUUGCC 1.2 ± 0.6d 11 ± 4 1.5 ± 0.1
3.8 ± 1.2e
C13.26 GGCGACCAUACGGGAGAGAAACUGCC 0.90 ± 0.03
C13.22 AGACCAUACGGGAGAGAAACUU 46 ± 9
C13.20 GACCAUACGGGAGAGAAACU 48 ± 7e 140 ± 10
C13.18 CCAUACGGGAGAGAAACU 35 ± 5d 220 ± 40 2,000 ± 400
See also Figure S1.
aC13.40 corresponds to nucleotides 35–74 of C13, with nucleotide numbers shown over the sequence. Residues corresponding to the 20 selected
nucleotides from C13 are underlined and flanking nucleotides are capable of forming an imperfect (C13.40) or perfect (C13.29, C13.28, C13.26,
C13.22) base-paired stem region. C13.29 was designed to include a 50 G overhang (Reyes et al., 2009). Each of these aptamers was cocrystallized
with GRK2 (see Table S1). The integrity of each aptamer was assessed by end labeling with [g-32P]ATP and radioimaging (Figure S6).
bActivity-based IC50 values ± SEM were measured in phosphorylation assays in three independent experiments.
cBinding IC50 values ± SEM were measured as decreased detection of bead-bound biotinylated GRK2 (bGRK2) in complex with Alexa Fluor 488-
labeled C13.28 (F-C13.28) in the presence of 0.5 nM F-C13.28 (see Figure S5). The data represent at least three different experiments performed
in duplicate.
dKd ± SEM was measured by a flow cytometry-based direct binding assay as a function of F-RNA-bGRK2 complex formation (see Figures S1A
and S1B).
eAs in (d), but detecting F-GRK2-bRNA complex formation (see Figure S1C).
Structure
Structure of GRK2 Bound to a Selective RNA Aptamerand outside the active site pocket of the kinase domain, and that
the terminal stem of the aptamer indirectly contributes to selec-
tivity by constraining the selected portion of the RNA.
RESULTS
Determinants ofGRK2Binding andSelectivity in theC13
Aptamer
To identify the regions of C13 that are important for GRK2
binding and to optimize the RNA for crystallographic analysis,
we synthesized a series of truncations and modifications of the
C13.51 variant of the aptamer (Mayer et al., 2008) (Table 1).
Our designs were also guided by concurrent X-ray diffrac-
tion experiments (Supplemental Experimental Procedures and
Table S1 available online). Our best structural models were of
GRK2 complexes with the C13.28 and C13.18 variants (Table 2).
C13.28 was designed to shorten the terminal stem of the orig-
inal aptamer to only four Watson-Crick base pairs, whereas
C13.18 lacks a terminal stem and two residues from the 50 end
of the 20 nucleotide variable region. To measure the direct
binding of GRK2 to C13.28 and C13.18, we used a flow cytom-
etry-based protein-RNA interaction assay (Blazer et al., 2010).
Biotinylated GRK2 (bGRK2) was first immobilized on streptavidin
beads and incubated with increasing amounts of 50 Alexa Fluor-
488-labeled C13.28 (F-C13.28) or C13.18 (F-C13.18). The beads
were then passed through a flow cytometer and the amount of
bead-bound fluorescencewas quantitated to yield a dissociation
constant (Kd) of 1.2 ± 0.6 and 35 ± 5 nM for F-C13.28 (Figure S1A)
and F-C13.18 (Figure S1B), respectively (Table 1). A similar
binding constant for C13.28 (Kd of 3.8 ± 1.2 nM) was measured
when the assay was reversed such that the 50 end of C13.28 was
biotinylated and bound to beads and incubated with fluores-
cently labeled GRK2 (F-GRK2) (Table 1 and Figure S1C). TheStructure 20, 1300Kd values for these RNAs correlate with their potency in inhibiting
GRK2-mediated phosphorylation of invertebrate rhodopsin, in
that C13.28 inhibited GRK2 phosphorylation 20-fold more
potently than C13.18 (IC50 values of 11 ± 4 and 220 ± 40 nM,
respectively) (Table 1). Furthermore, we confirmed that C13.28
shows selectivity toward GRK2 by measuring the RNA binding
to GRK1 and GRK6, representative members of the other
two branches of the GRK subfamily (Premont and Gainetdinov,
2007; Premont et al., 1999). In this assay, biotinylated C13.28
(bC13.28) was attached to streptavidin beads and incubated
with F-GRK2 for use in competition assays with unlabeled
GRKs (Figure S2). The IC50 for GRK2 (3.3 ± 0.3 nM) was 60
and 180-fold lower than the IC50’s measured for GRK6 and
GRK1 (210 ± 10 and 590 ± 160 nM), respectively, recapitulating
the selectivity properties of C13.
The relative affinity of the other RNA variants for bGRK2 was
determined in competition format by mixing F-C13.28 (0.5 nM)
with increasing amounts of unlabeled competitor RNA and
measuring the bead-associated fluorescence (Table 1). All
RNAs designed to retain a terminal stem of at least three
Watson-Crick base pairs (C13.40, C13.29, C13.28, and C13.26)
exhibited high affinity for bGRK2, with IC50 values ranging from
0.9 to 1.5 nM. Those that did not (C13.22, C13.20, and C13.18)
exhibited lower affinity by one to three orders of magnitude in
this assay format. Collectively, our binding data indicate that
the 18 nucleotides within the selected region of the aptamer
(C13.18) are sufficient for binding and inhibiting GRK2, but that
the terminal stem is necessary for high potency.
Structure of the C13.18-GRK2 Complex
Many C13 variants readily crystallized with GRK2 alone and/or
with the GRK2-Gbg complex (Table S1), but all exhibited diffrac-
tion from moderate to low resolution, most likely due to the–1309, August 8, 2012 ª2012 Elsevier Ltd All rights reserved 1301
Table 2. Crystallographic Data Statistics
Complexa C13.28-GRK2-Gb1g2 C13.18-GRK2
X-ray source APS 21-ID-G APS 21-ID-G
Wavelength (A˚) 0.97856 0.97856
Dmin (A˚) 4.5 (4.58–4.50) 3.5 (3.56–3.50)
Space group P312 P21212
Unit cell constants a = 257 A˚ a = 113.3 A˚
b = 257 A˚ b = 139.7 A˚
c = 99.4 A˚ c = 60.9 A˚
a = b = 90; g = 120 a = b = g = 90
No. crystals 1 2
Unique reflections 12,758 (96) 8,251 (92)
Average multiplicity 3.9 (2.3) 7.8 (8.3)
Rsym (%) 6.4 (38.8) 10.3 (49.0)
Completeness (%)b 58.4 (9.0) 65.5 (14.8)
h I i / h sI i 24.5 (1.6)c 28.9 (4.7)
Refinement resolution 20.0–4.52
(4.63–4.52)
25.0–3.51
(3.60–3.51)
Total reflections used 11,919 (154) 7,811 (87)
Protein atoms 8,112 4,746
Nonprotein atoms 401 168
Rmsd bond lengths (A˚) 0.005 0.005
Rmsd bond angles () 0.86 0.91
Established coordinate
error (A˚)
0.95 0.67
Ramachandran most
favored, disallowed (%)
83.1, 0.0 84.7, 0.0
Rwork (%) 18.4 (26.8) 21.6 (41.4)
Rfree (%) 26.8 (37.1) 31.7 (37.1)
PDB entry 3UZS 3UZT
See also Figure S1.
aThese crystal forms represent the best diffracting crystals of the various
aptamers in complex with GRK2 (see Tables 1 and S1).
bData sets were elliptically truncated to the maximum resolution in each
direction as described in the methods.
cA I/sI cutoff of 0 was applied to this crystal form during scaling.
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Structure of GRK2 Bound to a Selective RNA Aptamerflexible nature of RNA which was commonly observed in lattice
contacts. The best data were obtained from crystals of the
GRK2-C13.18 complex, which diffracted anisotropically to
3.5 A˚ spacings (Tables 2 and S1). The aptamer binds in the cleft
formed between the small and large lobes of the kinase domain
(Figures 1A and S3A), which differ in orientation by 8 relative to
those of previously reported structures of GRK2 determined in
the presence of ATP (e.g., PDB entries 1OMW [Lodowski et al.,
2003b] and 2BCJ [Tesmer et al., 2005]), and by 12 relative to
those of GRK6 in what is considered to be the most active con-
formation of a GRK determined to date (Boguth et al., 2010).
A smaller degree of domain reorientation was previously
observed in structures of GRK2 bound to small molecule inhibi-
tors (Tesmer et al., 2010; Thal et al., 2011). Aptamer-induced
domain remodeling has also been observed for an NF-kB
p50-aptamer complex (Huang et al., 2003).
Two segments of the kinase domain are disordered. The first
missing segment (amino acids 399–410) spans residues that1302 Structure 20, 1300–1309, August 8, 2012 ª2012 Elsevier Ltd Alconstitute the aG helix of the large lobe in other GRK2 structures
(faded green loop and helix in Figure 1B). Residues 391–398 that
precede this segment adopt a novel conformation compared to
previous structures (e.g., PDB entry 1OMW), such that they
extend away from the large lobe and form lattice contacts with
the 50 nucleotide of a symmetry-related RNA (Figures 1A, 1B,
and S3B). Conformational flexibility of the aF-aG loop/aG helix
region in GRKs is consistent with its proteolytic sensitivity in
GRK2 (Lodowski et al., 2005) and high temperature factors in
other GRK structures (Boguth et al., 2010; Lodowski et al.,
2005; Singh et al., 2008). The second missing segment (amino
acids 476–491) is part of the ‘‘active site tether,’’ a structural
element unique to AGC kinases that is expected to become
more ordered as the kinase domain approaches its active state
(Kannan et al., 2007). It is likewise disordered in prior GRK2
structures.
Omit maps revealed strong electron density for the first six
residues of C13.18 and the 50 phosphate of the seventh nucleo-
tide, allowing confident modeling of 47-CpCpApUpApCp-52
(Figures 1B and S3B). The RNA makes a tight turn that projects
A51 deep into the active site of the kinase such that its AMP
moiety and the preceding 50 phosphate of U50 essentially over-
lap with the AMP moiety and g phosphate of the physiological
substrate ATP (Figure 1C). Despite the low resolution of the
map, we modeled a Mg2+ ion in persistent positive jFoj-jFcj elec-
tron density between the U50 50 phosphate and GRK2-Asp335,
which would help neutralize the electrostatic repulsion between
these residues (Figure 1C). This Mg2+ ion is in a position analo-
gous to one of the two Mg2+ ions that are typically observed in
other AGC kinase$ATP complexes (Adams and Taylor, 1993;
Singh et al., 2008).
The overall conformation of C13.18 seems to be stabilized by
hydrogen bonds between N4 of C52 and the 20-OH of A49, and
between the 50-phosphate of C52 and the 20-OH of U50 (Fig-
ure 1C). The fold of the RNA is also probably influenced by its
extensive interactions with the kinase domain, which bury
1,140 A˚2 of accessible surface area. The RNA recapitulates
specific contacts made by the substrate ATP with the kinase
domain, including hydrophobic contacts with the A51 base
and hydrogen bonds to the ribose and adenine ring. Other inter-
actions appear mostly electrostatic in nature, including interac-
tions between the kinase and the U50 phosphate via Mg2+, as
well as between His280 and the phosphodiester backbone
(Figures 1B and S3B). The twelve unresolved nucleotides from
the 30 end of the C13.18 aptamer project into a cavity formed
with a symmetry related kinase domain, where they likely interact
electrostatically with positively charged residues that line the
cavity (Figure S3B).Interaction with the GRK2 Active Site Is Essential
for C13 Binding
Both ATP and staurosporine inhibit C13 aptamer binding to
GRK2 (Mayer et al., 2008), consistent with C13.18 occupying
the ATP-binding pocket of GRK2 in our structural model. We
further demonstrated that ADP acts as a competitive inhibitor
of the shorter C13.18 aptamer with an IC50 of 67 ± 22 mM (Fig-
ure 2A), a value consistent with the 30 mM Km measured for
ATP in phosphorylation reactions (Benovic et al., 1987) and thel rights reserved
Figure 1. The C13.18 Aptamer Binds in the Active Site of GRK2
(A) Overall structure of the C13.18-GRK2 complex. Residues 47-CCAUAC-52
of C13.18 are depicted as a cartoon ribbon with spokes indicating nucleotide
bases. The kinase, RH and PH domains of GRK2 are shown in yellow,
burgundy, and gray, respectively. Mg2+ is a black sphere. Asterisks demark
residues flanking disordered regions of the kinase domain: a segment of the
active site tether (amino acids 475 and 492, black) and a segment spanning the
aG helix of apo-GRK2 structures (amino acids 398 and 411, green). Aptamer
binding induces an 8 change in the orientation of the large and small lobes
(Figure S3A).
(B) Interactions of the C13.18 aptamer in the active site of GRK2. The blue wire
cage corresponds to a 2 mjFoj-DjFcj simulated annealing omit map contoured
Structure
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Structure 20, 130040 mM Ki measured for ADP in a fluorescence polarization
displacement assay (J.J.G.T., unpublished data).
Further validation of the C13.18-GRK2 model was gained
through mutating the RNA at positions that dock in the active
site of GRK2 and determining their ability to bind to GRK2 in
a filter retention assay (Figure 2B). Full-length radiolabeled C13
was synthesized in vitro and bound to GRK2 with an affinity of
92 ± 9 nM, consistent with previous measurements (Mayer
et al., 2008). The 100-fold higher Kd for the aptamer in this
assay compared with C13.28 in the flow-cytometry based assay
(Table 1) could reflect the fact that the polyanion heparin was
included as a nonspecific competitor in the filter-retention exper-
iments, or that complex formation was at 37C instead of 4C.
Among the five mutants created, only U50G bound with an
affinity similar to wild-type C13 (77 ± 9 nM). The wild-type
behavior of the U50G mutant is consistent with the fact that
the U50 base does not form specific interactions with either
the protein or the rest of the RNA in the GRK2-C13.18 structure
(Figure 1B). Four additional mutations (A49C, A51C, C52A, and
G53U) did not show detectable binding to GRK2 (Figure 2B).
The close packing interactions of GRK2 with the cytosine base
of C52, as well the specific hydrogen bond between C52 N4
and A49 20 OH (Figure 1B), likely explain why this base cannot
be substituted with a larger adenine ring. The inability to substi-
tute A51 with cytosine is consistent with the A51 base occupying
the canonical adenine-binding site of the kinase domain.
Because of their lack of direct base interactions with GRK2,
the loss of binding of the A49C and G53U mutants is most likely
explained by changes in the fold of the RNA, which could recon-
figure to form a duplex stem of 46-CCC-49/ 55-GGG-53 (the
A49C substitution) or 46-CCA-49/55-GGU-53 (the G53U substi-
tution). These stems would place A51 in the middle of a three
nucleotide hairpin loop that is unlikely to fit in the active site
pocket of GRK2.
We next demonstrated that A51 plays a pivotal role in the inhi-
bition of GRK2 activity by C13.28. C13.28 was synthesized with
an A51C mutation (C13.28A51C), and shown to be incapable of
binding GRK2 in our competition-based flow cytometry experi-
ments (Figure 2C). In activity assays, C13.28A51C did not inhibit
GRK2 phosphorylation of invertebrate rhodopsin at any concen-
tration tested (up to 2 mM), in striking contrast with C13.28, which
shows near complete inhibition at 50 nM (Figure 2D and Table 1).
Our structural model suggested that residues His280 and
Asp335 could play a pivotal role in binding C13 in the active
site, and these are among the few residues whose contacts to
C13.18 are independent of A51 and not dictated by backboneat 1 s around residues 47-CCAUAC-52 of C13.18. Carbons atoms are gray for
C13.18, and yellow for the kinase domain. Nitrogens are cyan, oxygens red,
phosphates orange and Mg2+ black. Intramolecular hydrogen bonds in the
RNA are dashed lines. The position of the aF-aG loop and aG helix in apo-
GRK2 (amino acids 391–410; PDB entry 2BCJ [Tesmer et al., 2005]) is shown in
green at half transparency and is reorganized in the C13.18-bound structure
(see also Figure S3A). The 12 C-terminal nucleotides of the aptamer are dis-
ordered, but extend into a crystal contact lined with positively charged amino
acids (Figure S3B).
(C) C13.18 mimics the binding of ATP in the GRK2 active site. GRK2-bound
ATP was homology modeled based on the GRK1$2Mg2+$ATP complex
(purple; PDB entry 3C4W (Singh et al., 2008)). The P loop was omitted for
clarity.
–1309, August 8, 2012 ª2012 Elsevier Ltd All rights reserved 1303
Figure 2. Nucleotides that Interact with the
Active Site of GRK2 are Essential for Binding
(A) ADP inhibits complex formation between
F-C13.18 and b-GRK2. Varying concentrations of
unlabeled competitor were included in binding
reactions with F-C13.18 (35 nM final concentra-
tion, corresponding to the Kd) and bGRK2 bound
to beads. Data from three separate experiments
were fit using a single-site competition model to
obtain IC50 values ± SEM for C13.28 (0.44 ±
0.19 nM), C13.18 (100 ± 41 nM), and ADP (67 ±
22 mM). A representative experiment is shown.
ADP exhibited a 40-fold higher IC50 in competition
against F-C13.28 (Figure S5).
(B) Impaired GRK2 binding by site-directed
mutation of residues in C13. In this filter-retention
assay, the percent of input radiolabeled wild-type
C13 or its single nucleotide mutants that bound to
GRK2 is plotted as a function of GRK2 concen-
tration. The Kd ± SEM for wild-type C13 and U50G
were 92 ± 9 and 77 ± 9 nM, respectively. GRK2
binding to A49C, A51C, C52A, and G53U was
not detectable. Data represent three independent
experiments.
(C) C13.28A51C does not compete for complex
formation between F-C13.28 and bGRK2. A
representative example ±SEM from three inde-
pendent flow cytometry experiments is shown.
(D) C13.28A51C does not inhibit phosphorylation
of invertebrate rhodopsin by GRK2. All samples
contained receptor and included GRK2 without
RNA (lane 1), no GRK2 (lane 2) and GRK2 with
2 mM C13.28-A51C (lane 3) or 50 nM C13.28
(lane 4). Shown is a representative autoradiogram
of the phosphorylated receptor, which was re-
solved on an SDS-PAGE gel.
Structure
Structure of GRK2 Bound to a Selective RNA Aptameratoms (e.g., the hinge of the kinase domain and the glycine-rich P
loop). We individually mutated His280 and Asp335 to alanine and
assayed these proteins for their ability to bind radiolabeled C13
in our filter-retention assay (Figure 3A). GRK2-D335A binding to
C13 was barely detectable, and the binding of GRK2-His280A
(Kd of 211 ± 5 nM) was 2-fold weaker than wild-type. Interest-
ingly, these samemutant proteins did not show impaired binding
to C13.28 in our flow-cytometry based assay, even when
150 mM NaCl was included in the binding buffer. We suspect
that heparin, which was included in the filter-binding assay to
reduce nonspecific RNA binding and has been shown to inhibit
GRKactivity (Loudon andBenovic, 1994), competes for a surface
of GRK2 that is recognized by the aptamer outside of the active
site. This could reduce the affinity of the aptamer for GRK2 to the
extent that we can detect the contribution of residues within the
active site.
Structure of the GRK2-C13.28 Complex
Further understanding of how C13 inhibits GRK2 was gained
from the crystal structure of the high-affinity C13.28 variant
bound to the GRK2-Gb1g2 complex, which was determined
using anisotropic diffraction data to 4.5 A˚ spacings (Figure 4
and Table 2). The overall conformation of the kinase domain
and lack of electron density for the aF-aG loop region in its
canonical configuration is essentially the same as observed
for the C13.18-GRK2 complex. The fold and shape of 49-1304 Structure 20, 1300–1309, August 8, 2012 ª2012 Elsevier Ltd AlApUpApCp-52 is likewise consistent between the two structures
(Figure 4A). Moreover, electron density for these nucleotides,
and absence of interpretable density for the aF-aG loop region,
was consistently observed in five other crystal forms of GRK2 in
complex with C13 variants (Table S1), indicating that they are not
an artifact of crystal packing. Outside the 49-ApUpApCp-52
sequence, the backbone of C13.28 takes a somewhat different
course from that of C13.18, which is likely influenced by the pres-
ence of a terminal stem in C13.28.
We observed strong electron density consistent with an
A-form double helix that was modeled as residues 41-GGCAG-
44 and 64-UUGCC-68 of C13.28 (Figure 4A). This helix is posi-
tioned such that the base of the 50 nucleotide stacks with its
symmetry-related equivalent at a two-fold axis of the crystal (Fig-
ure 4B). A continuous chain could then be built from the 50 end of
the RNA through the GRK2 active site (nucleotides 41–55). The
trajectory for the 50 end of C13.28 as it exits the active site is
consistent with the increasingly longer arms of electron density
that project from the active site in crystal structures that contain
RNA variants with progressively longer 50 ends (i.e., the crystal
structures of complexes with C13.18, C13.20, C13.22, and
C13.26, respectively) (Tables 1 and S1, and data not shown).
In the active site cleft, the base of G53 appears to be disordered,
as it is in the C13.18 structure, and G54 and G55 appear to be in
position to make Watson-Crick base pairs with C48 and C47,
respectively. As a result, the structure of C13.28 is similar to anl rights reserved
Figure 3. GRK2 Residues His280 and Asp335 and
the Basic aF-aG Loop Contribute to C13 Binding
(A) Filter retention analysis of the relative amount of
radioactively labeled C13 bound to wild-type GRK2 or its
mutants. Results are plotted as a function of protein
concentration, as described in Figure 2B. The Kd ± SEM
for C13 binding to wild-type GRK2 or GRK2 H280A was
91 ± 11 nM and 211 ± 55 nM, respectively. Weaker
affinity was observed for C13 binding to GRK2 FG-6A.
The interaction of C13 with GRK2 D335A was barely
detectable. Data represent at least two independent
experiments.
(B) Mutation of basic residues in the aF-aG loop of GRK2
decreases affinity of C13.28 for GRK2 in the flow cytom-
etry RNA-protein binding assay. IC50 ± SEM values for
wild-type GRK2 and GRK2-FG-6A, measured as a func-
tion of decreased detection of F-GRK2 in complex with
bead-bound C13.28, were 3.3 ± 0.3 and 510 ± 170 nM,
respectively. A representative experiment is shown.
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Structure of GRK2 Bound to a Selective RNA AptamerRNA duplex that terminates in a standard GNRA tetraloop
(Batey et al., 1999), such as that of the glycine riboswitch
(Huang et al., 2010), except that the loop of C13.28 is a pentaloop
(49-AUACG-53), and there is an eight nucleotide insertion within
the duplex region (Figures 4C and S4).
After refining our model for C13.28-GRK2-Gb1g2, two regions
of strong electron density (Density I and Density II) remained
(Figures 4A and S4). These regions likely correspond, at least in
part, to the eight unmodeled nucleotides (nucleotides 56–63),
which could easily traverse both volumes (Figure S4). The first
volume (Density I) is observed in all the RNA-GRK2 complexes
analyzed (Table S1 and data not shown) and is centered close
to the space that would have occupied by the aG helix, as it is
in prior GRK2 structures. In the C13.18-GRK2 structure, GRK2
residues 391–398 extend into Density I when superimposed
upon the C13.28-GRK2-Gb1g2 model, suggesting that Density I
could correspond to both RNA and remodeled residues from
the basic aF-aG loop region. Density II is adjacent to residues
350–358 of the GRK2 activation loop and was observed in all
aptamer complexes except that containing the shortest RNA,
C13.18. This result suggests that the conformation of the RNA
that generates Density II is dependent on the nucleotide
sequence immediately 50 to C47.
Basic Residues from the GRK2 aF-aG Loop Contribute
to C13 Binding
Aptamer binding correlates with structural reorganization of the
aF-aG loop of GRK2, and our electron density maps from the
GRK2-C12.28 structure suggest that this extremely basic loop
would be positioned in a manner that could help stabilize
aptamer binding. The competition profiles for F-C13.28 with
b-GRK2 were also suggestive of additional contacts outside
the active site, given the larger IC50 values for C13.18 and ADP
(see Table 1 and Figure S5).
To test the role of basic residues in the aF-aG loop region,
we simultaneously mutated GRK2-Arg392, -His394, -Lys395,
-Lys397, -Lys399, and His400 to alanine. Thermal denaturation
profiles of the resulting protein, GRK2-FG-6A, in the presence
and absence of ATP indicated that this protein is properly folded
and binds ATP (data not shown). In flow cytometry-based com-
petition assays, the IC50 of GRK2-FG-6A for displacing F-GRK2Structure 20, 1300bound to bC13.28 was 510 nM, which is over two orders of
magnitude greater than that of wild-type GRK2 (Figure 3B).
Our filter-binding assay confirmed a reduced affinity of C13 for
the GRK2-FG-6A variant (Figure 3A), but it was not as dramatic
as in the flow cytometry assay. Perhaps heparin, which is
included in the filter-retention assay, competes with the aptamer
for binding to this region of GRK2. Indeed, the basic residues of
the aF-aG region are most likely interacting with the phospho-
diester backbone of unmodeled nucleotides 56–63 of C13.28
that pass through Density I (Figure 4A).
DISCUSSION
The C13 aptamer inhibits GRK2 with high selectivity and affinity.
Our crystallographic structures and biochemical data demon-
strate that a small portion of this aptamer (49-AUAC-52) forms
extensive interactions with the catalytic cleft between the large
and small kinase domains of GRK2, stabilizing a unique confor-
mation of the enzyme that is consistent among seven unique
crystal forms. A sharp turn at A51 allows this nucleotide to insert
into the canonical ATP-binding site of the kinase domain, such
that the RNA mimics the binding of the substrate ATP. A51 is
key to binding of the aptamer, as ADP can completely inhibit
aptamer binding, and mutation of A51 eliminates both C13.28
binding and kinase inhibition. Furthermore, our structure and
mutagenesis studies show that a segment of the RNA backbone
thatmimics the g-phosphate of ATPmakes a critical contact with
GRK2-Asp335 through a bridging Mg2+ ion (Figures 1C and 3A).
Contacts outside of the highly conserved active site of GRK2
also clearly stabilize formation of the C13-GRK2 complex and
contribute to selectivity. In all of the GRK2-aptamer crystal struc-
tures analyzed, even those in which the aptamer lacks a terminal
stem, the aF-aG loop and aG helix is reconfigured from its posi-
tion in the apo-GRK2 structure to accommodate the 30 end of the
aptamer as it exits the active site. Our mutagenesis data show
that basic residues in this reconfigured region are essential for
high-affinity RNA binding, suggesting that they make favorable
electrostatic interactions with the RNA. Because all GRKs
possess a similarly basic aF-aG region, but adopt distinct inac-
tive conformations, we propose that the inactive conformation
of GRK2 best allows for efficient and simultaneous binding–1309, August 8, 2012 ª2012 Elsevier Ltd All rights reserved 1305
Figure 4. Structure of the C12.28-GRK2-Gb1g2 Complex Reveals the
Topology and Contacts of C13 outside the Active Site
(A) Crystal structure of C13.28 bound to GRK2-Gb1g2. GRK2 colors and
asterisks are the same as Figure 1A. Gb1 is blue and Gg2 green. A 5
0 segment
(G41- G55) and a 30 segment (U64-C68) of C13.28 are modeled with red
asterisks marking residues G55 and U64, which bracket the eight nucleotide
gap. Electron density from the final 2 mjFoj-DjFcj map contoured at 1 s and
from the final mjFoj-DjFcj map contoured at 3 s are shown as blue and green
wire cages, respectively. In the latter map there are two volumes of strong
unmodeled electron density (Density I andDensity II), which are likely traversed
by nucleotides 56–63 of the aptamer (Figure S4).
(B) The C13.28-GRK2-Gb1g2 complex crystallized in a D3 symmetric assembly
at 32 centers of the crystal. The geranylgeranylated C termini of Gg2 project
into a channel formed at the 3-fold axis of these hexamers. The kinase domain
and C13.28 project outward from the hexamer, with RNA-RNA crystal con-
tacts connecting symmetry related hexamers.
(C) Comparison of the topology of C13.28 (top) with nucleotides 42–68 of the
glycine riboswitch (Huang et al., 2010) (PDB entry 3OWI; bottom). The hairpin
loops (five nucleotides for C13.28 and a canonical GNRA tetraloop for the
riboswitch) are drawn with black carbons. In C13.28, there is an 8 nucleotide
insertion in the duplex in place of position 56 of the riboswitch (green).
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(Density I) and the activation loop region (Density II). In this way,
the malleability of the small and large lobes and of the aF-aG
loop region all contribute to aptamer selectivity. The terminal
stem that tethers the selected region of the aptamer also con-
tributes to selectivity and is critical for high-affinity binding to
GRK2, most likely by limiting the number of possible conforma-
tions for the selected RNA.
We conclude that although the positioning of A51 in the GRK2
active site is key for C13 binding, shape and charge complemen-
tarity between C13 and its large interaction surface on GRK2
contribute strongly to RNA affinity and selectivity. The aptamer
is therefore distinct from small molecule compounds, such as
balanol and those developed by Takeda Pharmaceuticals, which
achieve selectivity solely by reading out differences in conforma-
tion from within the active site of the kinase domain (Tesmer
et al., 2010; Thal et al., 2011). Our research opens the possibility
that the C13 aptamer can be used in a high-throughput displace-
ment assay to identify novel compounds that not only bind GRK2
with high selectivity and affinity, but also that target surfaces of
GRK2 outside the active site important for aptamer binding
(Hafner et al., 2006, 2008).
EXPERIMENTAL PROCEDURES
Reagents
C13 are variants listed in Table 1, and C13.28A51C and C13.28 50-labeled with
Alexa Fluor-488 (F-C13.28) and 50 amine-labeled C13.18, C13.20, and C13.28
were synthesized by Integrated DNA Technologies (Coralville, IA). All but the
amine-labeled RNAs were also high-performance liquid chromatography puri-
fied. Prior to flow cytometry and phosphorylation assays, these RNAs were
treated with a folding protocol (Supplemental Experimental Procedures).
Proteins expressed in baculovirus-infected insect cells were purified to
homogeneity essentially as described previously. These include bovine
GRK2-S670A (Lodowski et al., 2003a, 2003b), bovine Gb1g2 (Inglese et al.,
1992; Lodowski et al., 2003a, 2003b) (composed of untagged Gb1 and
N-terminally His-tagged g2), the palmitoylation-deficient C561S/C562S/
C565S variant of human GRK6 (Lodowski et al., 2006; Loudon and Benovic,
1997) and C-terminally His-tagged bovine GRK1 truncated at residue 535
which removes the farnesylation site (Singh et al., 2008) (Figure S2).
Flow Cytometry Protein-RNA Binding Assays
Either GRK2 or 50 amine-labeled RNA was biotinylated with biotinamidohexa-
noic acid N-hydroxysuccinimide (Sigma-Aldrich) and attached to SPHERO
streptavidin-coated particles (Spherotech). 50 Alexa Fluor-488-labeled
RNA (F-RNA) was synthesized either directly (F-C13.28) or with a 50 amine
that was subsequently labeled with Alexa Fluor-488 carboxylic acid, 2, 3, 5,
6-tetrafluorophenyl ester, 5-isomer (Invitrogen), the same reagent used
to fluorescently label GRK2 (F-GRK2). Increasing amounts of F-RNA (or
F-GRK2) were incubated with bGRK2- or bRNA-beads, respectively, in a
binding buffer consisting of 20 mM Tris (pH 7.0), 50 mM NaCl, 5 mM MgCl2,
2 mM DTT, and 0.1% Lubrol (without nonspecific RNA) for at least 1 hr at
4C in the dark. Samples were loaded through a Hypercyt (Intellicyt Corpora-
tion) onto an Accuri C6 Flow Cytometer to measure the median fluorescence
intensity at ambient temperature. The data were fit in Prism 5.0a. with a back-
ground correction corresponding to the fluorescence signal associated with
unbound beads. Despite this correction, the best fit for C13.28 and C13.20
data was a total binding site model. Background-corrected C13.18 data fit
best with a one site specific binding model. At least three independent exper-
iments of duplicate samples were analyzed.
To determine the selectivity of C13.28 for GRK2, F-GRK2 (2 nM final concen-
tration) wasmixedwith varying concentrations of unlabeled protein competitor
(GRK1, GRK2 variants, or GRK6) prior to the addition of bC13.28-beads (Fig-
ure S2). For each RNA, the data were fit in Prism 5.0a with nonlinear regressionl rights reserved
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constraints to calculate IC50 values. Three independent experiments were
performed in duplicate or triplicate.
To compare the binding affinity of ADP and different RNA variants to GRK2,
competition analysis was performed using bGRK2 and either F-C13.28 [0.5 nM
(Table 1) or 1.2 nM final concentration (Figure S5)] or F-C13.18 (35 nM final
concentration). Data were processed as described above.
Phosphorylation Assay
GRK2 phosphorylation was measured by modification of a standard protocol
(Pronin et al., 2002). GRK2 (50 nM final concentration) was preincubated
with varying amounts of RNA on ice for 15 min at twice their final concentra-
tion in a sample containing 2.5 ml of GRK2 (in 20 mM Tris [pH 8.0] and 50 mM
NaCl) and 2.5 ml of RNA (in 20 mM Tris [pH 8.0], 50 mM NaCl, and 5 mM
MgCl2). To this sample, 5 ml of a 2 3 phosphorylation mix was added to
give a final concentration of 20 mM Tris (pH 8.0), 25 mM NaCl, 2.5 mM
MgCl2, 100 mM [g-
32P] ATP and 5 mM cholate insoluble Sepia rhodopsin.
Samples were incubated for 5 min at room temperature in light. The reaction
was stopped with an equal volume of 2 3 SDS sample buffer. Quenched
samples were incubated for 30 min and resolved on a 10%–15% SDS-
PAGE gel. The gel was dried and exposed to a phosphorimager screen,
which was scanned by a Typhoon 9410 imager (GE Healthcare, Waukesha,
WI). Bands were quantitated with ImageQuant (version 5.2) software and
data were fit in Prism 5.0a with nonlinear regression using a single binding
site competition model to calculate IC50 values. Three independent experi-
ments were performed.
C13 Mutants and Filter Retention Assay
Point mutants of C13 were obtained by PCR-mediated overlap extension
(Heckman and Pease, 2007), as described in Supplemental Experimental
Procedures. For the filter retention assay, radiolabeled C13 or point mutants
were obtained by in vitro transcription using a-(32P)-GTP, purifiedwith aNucleo
Spin Extract II kit (Machery-Nagel, Germany), and analyzed by gel for their
integrity. To measure GRK2-RNA interactions, C13 or its point mutants were
incubated with increasing concentrations (0–1,000 nM) of human GRK2 in
a binding buffer (phosphate buffered saline with 3 mM MgCl2) supplemented
with 1 mg ml-1 heparin and 1 mg ml-1 bovine serum albumin, for 30 min at
37C. Subsequently, the incubation mix was passed through a 0.45 mm nitro-
cellulose membrane, washed three times with 200 ml binding buffer, and dried.
RNA retained on the membrane was quantified using a FLA-3000 with AIDA
Image software. Data were fitted to a one-site specific binding curve with
a 4 parameter Hill slope using GraphPad Prism 5. Using this nonlinear curve
fit, a Kd was determined from at least two independent measurements.
Crystallization and Harvesting Conditions
More than seven truncations of the C13 aptamer were crystallized in a variety
of space groups, either in complex with GRK2 or GRK2-Gb1g2, using the
hanging drop method and different crystallization conditions (Table S1,
Supplemental Experimental Procedures, and data not shown).
The C13.28-GRK2-Gb1g2 complex was isolated by gel filtration in 20 mM
HEPES (pH 8.0), 60 mM NaCl, 10 mM CHAPS, 5 mM MgCl2, and 2 mM
DTT. The complex gave an A260/A280 ratio of 1.36 ± 0.01 (n = 2), which corre-
sponds to approximately 90% protein and 10% nucleic acid (Sambrook and
Russell, 2001), as predicted for a 1:1 protein:RNA complex. The protein was
concentrated to 6 mg ml-1 and mixed 1:1 (v/v) at 4C with a well solution
consisting of 100 mM Tris pH 8.5, 200 mM NaCl and 3% PEG 8000. Crystals
appeared within approximately one week and grew to dimensions of 180 3
180 3 60 mm.
The C13.18-GRK2 complex was isolated by gel filtration in 20 mM HEPES
(pH 7.0), 50 mM NaCl, 5 mM MgCl2, and 2 mM DTT. The complex had an
A260/A280 ratio of 1.33 ± 0.05 (n = 2), which corresponds to approximately
90% protein and 10% nucleic acid (Sambrook and Russell, 2001), slightly
higher than the predicted 94% protein and 6% RNA. Diffraction-quality
crystals were formed by microseeding (Ramsland et al., 2001). The C13.18-
GRK2 complex (2 ml of 2 mg ml-1) was mixed with 2 ml of a well solution con-
sisting 100 mMMES (pH 5.9), 100 mMNaCl and 5% PEG 3350 supplemented
with 0.1 M glycine and 0.2 ml of microseed stock at 4C. Thin plates appeared
in about a week and grew to dimensions of 200 3 100 3 10 mm.Structure 20, 1300Both crystal forms were harvested by adding a cryoprotective solution
containing 30% glycerol directly to the crystallization drop (Supplemental
Experimental Procedures). Crystals were mounted on cryoloops and then
plunged into liquid nitrogen for data collection.
Data Collection and Structure Determination
Diffraction from crystals of C13.28-GRK2-Gb1g2 and C13.18-GRK2 was
collected at the Advanced Photon Source beam lines 21-ID-G on MAR CCD
detectors at 110 K. The data sets were highly anisotropic, and best results in
scaling and map quality were achieved by truncating the observed reflections
in ellipsoidal volumes extending to 3.5 A˚ along a* and b* and 5.5 A˚ along a* for
the C13.18-GRK2 data set, and to 4.5 A˚ along a* and b* and 7.2 A˚ along c* for
the C13.28-GRK2-Gb1g2 data set. The refinement statistics in Table S1 reflect
ellipsoidal truncation (Lodowski et al., 2003b), which was found to improve
thequalityofmaps,and thus thespherical completenessstatistics areatypically
low at high resolution. The structures were solved by molecular replacement
using either GRK2 or the GRK2-Gbg complex from PDB entry 1OMW as
a search model in the program Phaser (McCoy et al., 2007). Both structures
contain one complex per asymmetric unit. The structures were refined using
TLSand restrained refinement in REFMAC5 (Murshudovet al., 1997) alternating
with manual model building in O (Jones et al., 1991). The final model of C13.28-
GRK2-Gb1g2 contains amino acids 29–390, 411–475, and 490–671 of GRK2,
2–340 of Gb1, and 2–68 of Gg2, and nucleotides 41–55 and 64–68 of C13.28.
The final model of C13.18-GRK2 contains amino acids 30–398, 411–475,
492–545, 552–568, and 576–656 of GRK2 and nucleotides 47–52 of C13.18.
ACCESSION NUMBERS
Atomic models and structure factors for the C13.28-GRK2-Gb1g2 and C13.18-
GRK2 complexes have been deposited with the Protein Data Bank as entries
3UZS and 3UZT, respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, Supplemental
Experimental Procedures and Supplemental References and can be found
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